NeuroSearch, Abbott Announce Initiation of Phase I Study With ABT-560

NeuroSearch announced that its development and license partner Abbott has enrolled and dosed the first patients in a clinical Phase I study with the drug candidate ABT-560, which has the potential to treat a variety of nervous system disorders.

According to NeuroSearch and Abbott, ABT-560 is a neuronal nicotinic receptor modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.

Under the terms of the license agreement, Abbott has all rights to ABT-560 and will finance all costs relating to the development and commercialization of the drug, the companies said. NeuroSearch will receive milestone payments and royalties on Abbott’s global sales if the drug is successfully commercialized, the companies added.